Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Gregg Lucksinger"'
Autor:
Mark Turner, Athanasia Papadimitriou, Peter Winkle, Nathan Segall, Michael Levin, Matthew Doust, Casey Johnson, Gregg Lucksinger, Carlos Fierro, Paul Pickrell, Marsha Raanan, Vianney Tricou, Astrid Borkowski, Derek Wallace
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 16, Iss 10, Pp 2456-2464 (2020)
Takeda has developed a live-attenuated dengue tetravalent vaccine candidate (TAK-003) which has been shown to be immunogenic with acceptable reactogenicity in phase 1 trials. In agreement with World Health Organization prequalification requirements f
Externí odkaz:
https://doaj.org/article/d90c64eee6d349779c7a59a1d82cece9
Autor:
Carlos Fierro, Casey Johnson, Athanasia Papadimitriou, Matthew Doust, Nathan Segall, Peter Winkle, Marsha Raanan, Mark Turner, Astrid Borkowski, Vianney Tricou, Paul Pickrell, Gregg Lucksinger, Derek Wallace, Michael Levin
Publikováno v:
Human Vaccines & Immunotherapeutics
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Takeda has developed a live-attenuated dengue tetravalent vaccine candidate (TAK-003) which has been shown to be immunogenic with acceptable reactogenicity in phase 1 trials. In agreement with World Health Organization prequalification requirements f
Autor:
Kathrin U. Jansen, Gregg Lucksinger, John L. Perez, Laura J. York, Judith Absalon, Angela Quinn, Mette E. Graversen, Lars Østergaard, Joseph Eiden, Johannes Beeslaar
Publikováno v:
Ostergaard, L, Lucksinger, G H, Absalon, J, Beeslaar, J, Eiden, J, Jansen, K U, York, L J, Quinn, A, Graversen, M E & Perez, J L 2016, ' A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults ', Vaccine, vol. 34, no. 12, pp. 1465-1471 . https://doi.org/10.1016/j.vaccine.2016.01.044
Østergaard, L J, Lucksinger, G H, Absalon, J, Beeslaar, J, Eiden, J, Jansen, K U, York, L J, Quinn, A, Graversen, M E & Perez, J L 2016, ' A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults ', Vaccine . https://doi.org/10.1016/j.vaccine.2016.01.044
Østergaard, L J, Lucksinger, G H, Absalon, J, Beeslaar, J, Eiden, J, Jansen, K U, York, L J, Quinn, A, Graversen, M E & Perez, J L 2016, ' A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults ', Vaccine . https://doi.org/10.1016/j.vaccine.2016.01.044
Background: Neisseria meningitidis serogroup B (MnB) is an important cause of invasive meningococcal disease (IMD). A MnB vaccine (bivalent rLP2086, Trumenba®) consisting of 2 factor H binding protein variants received accelerated approval in the Un
Autor:
William Koltun, Peter A. Leone, Seth Hetherington, Anna Wald, Bin Zhang, Lori Panther, Gregg Lucksinger, Terri Warren, Richard H. Beigi, Sybil Tasker, David I. Bernstein, Nicholas Van Wagoner, Stephen K. Tyring, John D. Kriesel, Kenneth H. Fife, Richard M. Novak, Amy Morris, Lisa K. McNeil
Publikováno v:
J Infect Dis
Background GEN-003 is a candidate therapeutic vaccine for genital herpes simplex virus type 2 (HSV-2). We compared virologic and clinical impact of varying GEN-003 doses. Methods Adults with symptomatic HSV-2 received placebo or GEN-003 (30 or 60 µg
Autor:
Mo Weijtens, Lauren Peter, Glenda Gray, Katleen Callewaert, Erica N. Borducchi, David C. Montefiori, Thomas B. Campbell, Frank Tomaka, Kathy Mngadi, Fatima Laher, Joseph P. Nkolola, David Jetton, Jenny Hendriks, Roland Zahn, Frances Priddy, Edith Swann, Juliet Mpendo, Sorachai Nitayapan, Karin Feddes-de Boer, Wenjun Li, Stephan Bart, Erica Lazarus, Abishek Chandrashekar, Jennifer Johnson, Frank Wegmann, Steven Nijs, Lindsey R. Baden, Merlin L. Robb, Nigel Garrett, Ludo Lavreys, Galit Alter, Dan H. Barouch, Etienne Karita, Hanneke Schuitemaker, Daniel J. Stieh, Georgia D. Tomaras, Nicole Frahm, M. Juliana McElrath, Danielle van Manen, Zelda Euler, Gregg Lucksinger, Lorenz Scheppler, Hannah Kibuuka, Robert Feldman, Raphaele Roten, Maria G. Pau, Kathryn E. Stephenson, Caroline Borremans, Nelson L. Michael, Punnee Pitisuttithum, Jessica Vreugdenhil, Jeroen Tolboom, Jerald C. Sadoff, Kundai Chinyenze, Bette T. Korber, Julia Hutter
Publikováno v:
Lancet, 392(10143), 232-243. Elsevier Limited
Summary Background More than 1·8 million new cases of HIV-1 infection were diagnosed worldwide in 2016. No licensed prophylactic HIV-1 vaccine exists. A major limitation to date has been the lack of direct comparability between clinical trials and p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6169a5479eb278fd28c754f353bca4e7
https://pure.amc.nl/en/publications/evaluation-of-a-mosaic-hiv1-vaccine-in-a-multicentre-randomised-doubleblind-placebocontrolled-phase-12a-clinical-trial-approach-and-in-rhesus-monkeys-nhp-1319(234e01f2-b4e8-4e15-ba68-ebe28532f079).html
https://pure.amc.nl/en/publications/evaluation-of-a-mosaic-hiv1-vaccine-in-a-multicentre-randomised-doubleblind-placebocontrolled-phase-12a-clinical-trial-approach-and-in-rhesus-monkeys-nhp-1319(234e01f2-b4e8-4e15-ba68-ebe28532f079).html
Autor:
Cynthia Strout, Matthew Davis, Gregg Lucksinger, Langzhou Song, Casey P. Johnson, Katalin G. Abraham, Ge Liu, Scott Umlauf, Lynda Tussey, C. Jo White
Publikováno v:
Open Forum Infectious Diseases
Control of seasonal and pandemic influenza represents a global public health challenge due to the virus's ability to circumvent protective immune responses through frequent mutation and subunit recombination. These characteristics, coupled with influ
Autor:
Lisa K. McNeil, Win S, Natenshon A, Kenneth H. Mayer, Jessica Flechtner, Van Wagoner N, David I. Bernstein, Seth Hetherington, William Koltun, Thomas Oliphant, Anna Wald, Thomas C. Heineman, Gregg Lucksinger, Desai N, Peter A. Leone
Publikováno v:
Open Forum Infectious Diseases
Background GEN-003 is an investigational genital herpes immunotherapy comprising gD2ΔTMR, an HSV-2 antigen that induces neutralizing antibody and T cell responses, ICP4.2, an HSV-2 T cell antigen selected through human T cell screens, and Matrix-M2
Autor:
Gregg Lucksinger, Seth Hetherington, Kenneth H. Fife, David I. Bernstein, Stephen K. Tyring, Richard M. Novak, Jason Chan, Peter A. Leone, Sybil A. Tasker, Nicholas Van Wagoner, John D. Kriesel, Jacob Lalezari, Lori Panther, Richard H. Beigi, William Koltun, Terri Warren, Anna Wald
Publikováno v:
Open Forum Infectious Diseases. 2
RESULTS: Patient Demographics 898 1The University of Alabama at Birmingham, Birmingham, AL, 2Medical Center for Clinical Research, San Diego, CA, 3Tekton Research, Austin, TX, 4Westover Heights Clinic, Portland, OR, 5Center for Clinical Studies, Hous